Ebola Outbreak 2026: What You Need to Know About the Bundibugyo Virus Emergency in DRC and Uganda

Bundibugyo Virus Outbreak Reaches 915 Cases as WHO Warns of Regional Spread

The World Health Organization (WHO) has reported that the Ebola disease outbreak caused by the Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda has reached 915 confirmed cases and 234 deaths as of June 18, 2026. Declared a Public Health Emergency of International Concern (PHEIC) on May 17, this outbreak now represents the largest and most widespread Bundibugyo virus event ever recorded.

Unlike previous Ebola outbreaks, this one is caused by the Bundibugyo virus (Orthoebolavirus bundibugyoense) — a distinct species for which no licensed vaccine or specific antiviral treatment currently exists. This critical gap in the medical toolkit has made the outbreak particularly difficult to contain, especially given the complex humanitarian and conflict-affected environment in which it is unfolding.

The Current Situation: Key Numbers

As of the latest WHO Disease Outbreak News update, the outbreak figures paint a sobering picture of sustained transmission:

• Total confirmed cases: 915 (896 in DRC, 19 in Uganda)
• Total deaths: 234 (232 in DRC, 2 in Uganda)
• Case fatality rate (CFR) in DRC: 26% (likely underestimation due to underinvestigation of early deaths)
• Patients recovered: 88 (78 in DRC, 10 in Uganda)
• Affected health zones in DRC: 33 across Ituri (21), North Kivu (11), and South Kivu (1) provinces
• Epicentre: Ituri Province, accounting for 91.1% of confirmed cases (817 cases)
• Contacts under follow-up: 6,367 across all affected provinces

The outbreak remains concentrated in Ituri Province, with Bunia health zone reporting 247 cases, Rwampara 195 cases, Mongbwalu 189 cases, and Nyankunde 68 cases. Four additional health zones have reported new cases since the previous WHO update, though investigations suggest transmission may have been occurring undetected in these areas for weeks before confirmation.

Uganda’s Status: Imported Cases Under Control

Uganda has reported 19 confirmed cases, including two deaths, primarily linked to cross-border transmission from DRC. All cases have been concentrated in the Kampala Metropolitan Area, specifically Kampala and Wakiso districts. Of these, 14 are imported cases and five represent secondary transmission among contacts and healthcare workers.

Encouragingly, Uganda has not reported any new cases since June 5, 2026, and there has been no documented community transmission within the country. Of the 826 contacts listed, 694 have completed their 21-day follow-up period, suggesting the outbreak may be contained on the Ugandan side.

Why This Outbreak Is Different

The Bundibugyo virus was first identified in Uganda in 2007 and has only caused three known outbreaks: Uganda in 2007–2008, DRC in 2012, and the current 2026 outbreak. This is the 17th Ebola disease outbreak DRC has experienced since 1976, but only the third involving the Bundibugyo species.

What makes this outbreak uniquely challenging is the absence of approved countermeasures. The two licensed Ebola vaccines — Ervebo (rVSV-ZEBOV) and the two-dose Ad26.ZEBOV/MVA-BN-Filo regimen — are only approved for the Zaire Ebola virus (formerly known as Ebola virus), not for Bundibugyo. Similarly, the monoclonal antibody treatments that proved effective during the 2018–2020 DRC outbreak targeted Zaire virus and have not demonstrated efficacy against Bundibugyo.

According to Doctors Without Borders/Médecins Sans Frontières (MSF), discussions are underway within the WHO to determine which vaccine candidates could be tested in emergency clinical trials for the Bundibugyo virus. MSF has indicated readiness to contribute to this research, as they did during the 2019 DRC trials that led to the approval of current Ebola vaccines and treatments.

CDC Risk Assessment and U.S. Response

The U.S. Centers for Disease Control and Prevention (CDC) has assessed the risk to the American public as low. However, the agency has taken several precautionary measures:

• Travel Health Notices issued: Level 3 for DRC (avoid non-essential travel to Ituri, North Kivu, and South Kivu provinces), Level 2 for Uganda
• Enhanced screening at U.S. airports: Affected air passengers from DRC, South Sudan, and Uganda are being re-routed to Washington-Dulles (IAD), Atlanta (ATL), Houston (IAH), or New York JFK for enhanced screening
• CDC modeling: A published CDC analysis (MMWR) projects potential outbreak scenarios and underscores the need for immediate, strong public health intervention to control the spread
• Health Alert Network (HAN) notice issued: To alert U.S. healthcare systems and public health departments

One American citizen who contracted Ebola while performing humanitarian work in DRC has since recovered and been released from care. High-risk contacts associated with this case have all completed their 21-day monitoring period without developing symptoms.

Response Efforts on the Ground

National authorities in DRC and Uganda, in collaboration with WHO, MSF, the Africa CDC, and other partners, are implementing a comprehensive response that includes:

• Surveillance and contact tracing: Over 6,300 contacts identified and being monitored across three provinces
• Diagnostic scale-up: Testing capacity has been expanded, clearing backlogs of previously collected samples
• Infection prevention and control (IPC): Training and equipping healthcare facilities in affected areas
• Community engagement: Response efforts anchored in local leadership given the complex security environment
• Safe burial practices: Protocols to prevent transmission during funerals
• Cross-border coordination: A regional preparedness and prioritization framework guiding readiness across the African Region

The outbreak is unfolding in a complex humanitarian setting characterized by highly mobile and displaced populations, limited access to basic services, overcrowded internally displaced camps, and security incidents affecting health facilities. These factors have constrained access for response teams and heightened the risk of undetected transmission.

Symptoms of Bundibugyo Virus Disease

Bundibugyo virus disease (BVD) presents with symptoms similar to other forms of Ebola disease. The incubation period ranges from 2 to 21 days, and individuals are not infectious until symptoms begin. Key symptoms include:

• Fever and severe weakness
• Headache and muscle pain
• Vomiting and diarrhea
• Abdominal pain
• Nosebleeds and bleeding from gums
• Blood in vomit or stool (in severe cases)

In the absence of a specific treatment, care relies on intensive supportive therapy: fluid replacement, oxygen support, electrolyte management, and close cardiac and blood monitoring. Early supportive care has been shown to significantly improve survival outcomes.

Frequently Asked Questions (FAQ)

What is the Bundibugyo virus?

The Bundibugyo virus is one of four orthoebolavirus species that cause Ebola disease in humans. It was first discovered in Uganda’s Bundibugyo District in 2007 and has a case fatality rate historically ranging from 25% to 55%.

Is there a vaccine for the Bundibugyo virus?

No. Existing Ebola vaccines are only approved for the Zaire Ebola virus. Emergency clinical trials for Bundibugyo vaccine candidates are under discussion at WHO level.

Is there a treatment?

There is no approved specific treatment for Bundibugyo virus disease. Care is supportive, focused on managing symptoms and providing intensive care such as fluid replacement and oxygen therapy.

How is it transmitted?

The virus spreads through direct contact with blood, secretions, organs, or other bodily fluids of infected individuals, or with contaminated surfaces and materials. Transmission is amplified in healthcare settings with inadequate IPC measures and during unsafe burial practices.

Should I be concerned about travel?

The CDC recommends avoiding non-essential travel to Ituri, North Kivu, and South Kivu provinces in DRC. Travelers to DRC or Uganda should monitor for symptoms for 21 days after leaving affected areas. The risk to the general international public remains low.

Could this become a global pandemic?

While the outbreak is the largest Bundibugyo outbreak on record, WHO and CDC assessments indicate that with adequate international support and response measures, containment is achievable. The risk of widespread global transmission is considered low due to the virus’s mode of transmission (direct contact, not airborne).

What This Means for Global Health Security

The 2026 Bundibugyo outbreak is a stark reminder that gaps remain in our pandemic preparedness. Despite significant advances in Ebola countermeasures following the devastating 2014–2016 West Africa epidemic, those tools are strain-specific and do not cover all orthoebolavirus species.

The outbreak also highlights the critical importance of early detection, robust surveillance systems, and rapid international coordination. The fact that transmission may have been occurring undetected for weeks before the outbreak was officially declared underscores the need for strengthened diagnostic capacity in conflict-affected regions.

As this situation continues to evolve, Health Professional Radio will provide ongoing updates on the response efforts, scientific developments regarding potential vaccines and treatments, and public health guidance for our readers.

Sources: World Health Organization (WHO) Disease Outbreak News, CDC Health Alert Network, Doctors Without Borders/MSF, European Centre for Disease Prevention and Control, ReliefWeb.